CINXE.COM

Sciinov Group

<!DOCTYPE html> <html lang="en"> <meta http-equiv="content-type" content="text/html;charset=utf-8" /> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta http-equiv="X-UA-Compatible" content="ie=edge"> <title>Sciinov Group</title> <link rel="apple-touch-icon" sizes="180x180" href="assets/images/favicon/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="assets/images/favicon/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="assets/images/favicon/favicon-16x16.png"> <link rel="manifest" href="assets/images/favicon/site.webmanifest"> <!-- For Window Tab Color --> <!-- Chrome, Firefox OS and Opera --> <meta name="theme-color" content="#cd2828"> <!-- Windows Phone --> <meta name="msapplication-navbutton-color" content="#cd2828"> <!-- iOS Safari --> <meta name="apple-mobile-web-app-status-bar-style" content="#cd2828"> <link href="https://fonts.googleapis.com/css?family=Arimo:400,400i,700,700i%7CMerriweather:400i&amp;display=swap" rel="stylesheet"> <!-- plugins styles --> <link rel="stylesheet" href="assets/css/animate.css"> <link rel="stylesheet" href="assets/css/bootstrap.min.css"> <link rel="stylesheet" href="assets/css/bootstrap-datepicker.min.css"> <link rel="stylesheet" href="assets/css/bootstrap-select.min.css"> <link rel="stylesheet" href="assets/css/hover-min.css"> <link rel="stylesheet" href="assets/css/magnific-popup.css"> <link rel="stylesheet" href="assets/css/owl.carousel.min.css"> <link rel="stylesheet" href="assets/css/owl.theme.default.min.css"> <link rel="stylesheet" href="assets/css/nouislider.css"> <link rel="stylesheet" href="assets/css/nouislider.pips.css"> <link rel="stylesheet" href="assets/css/jquery.bootstrap-touchspin.min.css"> <link rel="stylesheet" href="assets/css/jquery.mCustomScrollbar.min.css"> <!-- icon styles --> <link rel="stylesheet" type="text/css" href="assets/css/politaro-icons.css"> <link rel="stylesheet" type="text/css" href="assets/css/simple-line-icons.css"> <link rel="stylesheet" type="text/css" href="assets/css/fontawesome-all.min.css"> <!-- main styles --> <link rel="stylesheet" href="assets/css/style.css"> <link rel="stylesheet" href="assets/css/responsive.css"> </head> <body> <div class="preloader" style="background-image: url(assets/images/resources/preloader.svg);"></div><!-- /.preloader --> <div class="page-wrapper"> <div class="site-header__header-one-wrapper"> <header class="site-header site-header__header-one "> <nav class="navbar navbar-expand-lg navbar-light header-navigation stricky"> <div class="container clearfix"> <!-- Brand and toggle get grouped for better mobile display --> <div class="logo-box"> <a class="navbar-brand" href="index.php"> <img src="https://sciinovgroup.com/uploads/images/11640844025.png" class="main-logo" alt="Awesome Image" /> </a> <button class="menu-toggler side-menu__toggler"> <span class="fa fa-bars"></span> </button> </div><!-- /.logo-box --> <!-- Collect the nav links, forms, and other content for toggling --> <div class="main-navigation main-nav__main-navigation"> <ul class=" navigation-box " id="mainNav"> <li class=" dropdown"><a href="index.php">HOME</a></li><!--current--> <li><a href="#about" class="">ABOUT US</a></li> <li><a href="#divisions">DIVISIONS </a> <ul> <li><a href="https://caucuscentric.com/" target="_blank">Caucus Centric </a></li> <li><a href="https://siconnects.com/" target="_blank">Siconnects </a></li> <li><a href="https://insights.sciinovgroup.com/" target="_blank">Sciinov Insights </a></li> <li><a href="https://tech.sciinovgroup.com/" target="_blank">SciTechnologies </a></li> <li><a href="https://sciinovhr.com/" target="_blank">SciinovHR Solutions </a></li> <li><a href="https://www.sciinovhealthcare.com/" target="_blank">Sciinov Healthcare </a></li> </ul> </li> <li><a href="#contact">REQUEST INFO</a></li> </ul> </div><!-- /.navbar-collapse --> <div class="right-side-box"> <a href="contact.php" class="thm-btn header-donation__btn">Get in Touch</a> </div><!-- /.right-side-box --> </div> <!-- /.container --> </nav> </header><!-- /.site-header --> </div> <section class="inner-banner" style="background-image: url(assets/images/backgrounds/inner-banner-about-bg.jpg);"> <div class="container text-center"> <h2 class="inner-banner__title">News and Announcements</h2><!-- /.inner-banner__title --> <ul class="list-unstyled thm-breadcrumb"> <li><a href="index.php">Home</a></li> <li>News and Announcements</li> </ul><!-- /.thm-breadcrumb --> </div><!-- /.container --> </section><!-- /.inner-banner --> <section class="about-three mt-5 pt-4 pb-2" > <div class="container "> <div class="row"> <div class="col-lg-12 shadow-lg mb-5"> <div class="about-three__content"> <div class="block-title text-left" style="margin-bottom: 5px;margin-top: 20px;"> <div class="blog-one__single"> <h3><a >Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa (copanlisib) and rituximab in the U.S. and EU</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a ><i class="far fa-calendar"></i>06/21/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.block-title --> <div class="about-three__text"> <p>In the U.S., Bayer has filed for relapsed indolent B-cell non-Hodgkin&rsquo;s Lymphoma (iNHL)</p> <p>In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted</p> <p>Bayer announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of the investigational combination of the cancer treatments Aliqopa&reg; (copanlisib) and rituximab. The U.S. submission is for the treatment of patients with relapsed indolent B-cell non-Hodgkin&rsquo;s Lymphoma (iNHL) and is outside of the FDA accelerated approved indication for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted. The submissions are supported by positive results from the Phase III trial CHRONOS-3, which were presented in April at the American Association for Cancer Research (AACR) Annual Meeting 2021, and simultaneously published in The Lancet Oncology.1 Indolent NHL consists of the following subtypes: FL, MZL, small lymphocytic lymphoma (SLL) and lymphoplasmacytoid lymphoma/Waldenstr&ouml;m macroglobulinemia (LPL/WM).</p> <p>&ldquo;The U.S. and EU submissions of the novel combination of Aliqopa and rituximab bring us forward in advancing new treatment approaches and addressing unmet needs of patients with different types of relapsed iNHL,&rdquo; said Scott Z. Fields, M.D., Senior Vice President and Head of Oncology Development at Bayer. &ldquo;We are excited about the potential of this investigational combination therapy based on the findings from CHRONOS-3 and we look forward to working with global regulatory authorities.&rdquo;</p> <p>The FDA has granted Orphan Drug Designations (ODD) for Aliqopa in chronic lymphocytic leukemia (CLL)/SLL and LPL/WM, and has previously granted an ODD for Aliqopa in FL and MZL. Additionally, Aliqopa was granted Breakthrough Therapy Designation for relapsed MZL in patients who have received at least two prior therapies. Bayer has also previously received an ODD for MZL in the EU.</p> <p>In 2017, Aliqopa was approved for the treatment of adult patients with relapsed FL who have received at least two prior systemic therapies based on the results of a single-arm, multi-center, Phase II clinical trial (CHRONOS-1).2 Accelerated approval was granted for this indication based on overall response rate (ORR). Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.</p> <p>CHRONOS-3 is a Phase III randomized, double-blind, placebo-controlled trial with the objective to evaluate whether Aliqopa in combination with rituximab is superior to placebo plus rituximab in extending progression-free survival (PFS) in patients with relapsed iNHL following at least one prior rituximab-containing therapy. Histological subtypes included in the trial were FL, SLL, LPL/WM, and MZL. Patients who had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing regimen or patients unwilling/unfit or for who chemotherapy was contraindicated by reason of age, co-morbidities and/or residual toxicity were included (NCT02367040). The study enrolled 458 participants.</p> </div><!-- /.about-three__text --> </div><!-- /.about-three__content --> </div><!-- /.col-lg-6 --> </div><!-- /.row --> </div><!-- /.container --> </section><!-- /.about-three --> <section class="mailchimp-one " id="contact"> <div class=" text-center"> <div class="inner-container wow fadeInUp" data-wow-duration="1500ms" style=" padding-bottom: 24px;"> <div class="row justify-content-center"> <div class="col-md-9"> <div class="mailchimp-one__block-title"> <h3>Have a business Query? Let's Talk.</h3> <p class="mt-3">Email : info@sciinovgroup.com or Call : USA: +1 732 526 1166 <br> India: +91 7997224449</p> </div><!-- /.mailchimp-one__block-title --> <div class="cta-one" style="padding-bottom: 0;"> <div class="inner-container wow fadeInUp" style="background-color: #114f9a;padding-top: 20px;padding-bottom: 30px;"> <div class="cta-one__content"> <p>Get The Latest Updates</p> <h3><span>Signup For Newsletter</span></h3> </div><!-- /.cta-one__content --> <div class="cta-one__btn-block"> <form action="" method="post" class=""> <input type="email" required placeholder="Enter Your Email...." name="email" style="margin-left: -37px;"> <button type="submit" name="sbmt" value="submit" class="thm-btn">subscribe</button> </form> </div><!-- /.cta-one__btn-block --> </div> </div> </div><!-- /.inner-container --> <div class="mc-form__response"></div><!-- /.mc-form__response --> </div><!-- /.container --> </div> </div> </section><!-- /.mailchimp-one --> <section class="site-footer__wrapper "> <div class="site-footer__upper"> <div class="container"> <div class="site-footer__logo"> <a href="index.php"><img src="https://sciinovgroup.com/uploads/images/11640844025.png" alt="Awesome Image" /></a> </div><!-- /.site-footer__logo --> <div class="site-footer__counter"> <div class="site-footer__counter-single"> <p><a href="https://sciinovgroup.com/about.php">About Us</a></p> </div><!-- /.site-footer__counter-single --> <div class="site-footer__counter-single"> <p><a href="https://sciinovgroup.com/contact.php">Contact Us</a></p> </div><!-- /.site-footer__counter-single --> <div class="site-footer__counter-single"> <p><a href="https://sciinovgroup.com/privacy-policies.php">Privacy Policy</a></p> </div><!-- /.site-footer__counter-single --> <div class="site-footer__counter-single"> <p><a href="https://sciinovgroup.com/terms-conditions.php">Terms and Conditions</a></p> </div><!-- /.site-footer__counter-single --> <div class="site-footer__counter-single"> <p><a href="https://sciinovgroup.com/refund-policy.php">Refund Policy</a></p> </div><!-- /.site-footer__counter-single --> </div><!-- /.site-footer__counter --> </div><!-- /.container --> </div><!-- /.site-footer__upper --> <footer class="site-footer"> <div class="container"> <div class="row no-gutters"> <footer class="row grid"> <div class="col-md-12"> <div class="copyright"> <div> </div> <address> <p>All divisions owned by Sciinov Group.<br /> <strong>Asia-Pacific:</strong>&nbsp;234C, 8th Street, Western Hills, KPHB, Hyderabad</p> </address> </div> </div> </footer> </div><!-- /.row --> </div><!-- /.container --> </footer><!-- /.site-footer --> <div class="site-footer__bottom"> <div class="container "> <div class="row "> <div class="col-sm-6"> <p>&copy; 2021 <a href="#">Sciinov Group</a>. All rights reserved.</p> </div> <div class="col-sm-6"> <div class="footer-widget__social"> <a href="https://twitter.com/gender_congress" target="_blank"><i class="fab fa-twitter"></i></a> <a href="https://www.facebook.com/Sciinov/" target="_blank"><i class="fab fa-facebook"></i></a> <a href="https://www.linkedin.com/company/sciinovgroup/" target="_blank"><i class="fab fa-linkedin"></i></a> </div> </div> </div> </div><!-- /.container --> </div><!-- /.site-footer__bottom --> </section><!-- /.site-footer__wrapper --> <script src='https://www.google.com/recaptcha/api.js'></script> </div><!-- /.page-wrapper --> <div class="side-menu__block"> <a href="#" class="side-menu__toggler side-menu__close-btn"> <i class="fa fa-times"></i> </a> <div class="side-menu__block-overlay custom-cursor__overlay"> <div class="cursor"></div> <div class="cursor-follower"></div> </div><!-- /.side-menu__block-overlay --> <div class="side-menu__block-inner "> <a href="index.php" class="side-menu__logo"><img src="https://sciinovgroup.com/uploads/images/11640844025.png" alt="Awesome Image" /></a> <nav class="mobile-nav__container"> <!-- content is loading via js --> </nav> <p class="side-menu__block__copy">(c) 2021 <a href="#" class="text-uppercase">Sciinov Group</a> - All rights reserved.</p> <div class="side-menu__social"> <!-- only fontawesome's brand icon --> <a href="#"><i class="fa fa-facebook-f"></i></a> <a href="#"><i class="fa fa-linkedin-in"></i></a> <a href="#"><i class="fa fa-twitter"></i></a> <a href="#"><i class="fa fa-instagram"></i></a> <a href="#"><i class="fa fa-pinterest-p"></i></a> </div> </div><!-- /.side-menu__block-inner --> </div><!-- /.side-menu__block --> <a href="#" data-target="html" class="scroll-to-target scroll-to-top"><i class="fa fa-angle-up"></i></a> <script src="assets/js/jquery.min.js"></script> <script src="assets/js/bootstrap.bundle.min.js"></script> <script src="assets/js/bootstrap-datepicker.min.js"></script> <script src="assets/js/bootstrap-select.min.js"></script> <script> // Cache selectors var lastId, topMenu = $("#mainNav"), topMenuHeight = topMenu.outerHeight()+1, // All list items menuItems = topMenu.find("a"), // Anchors corresponding to menu items scrollItems = menuItems.map(function(){ var item = $($(this).attr("href")); if (item.length) { return item; } }); // Bind click handler to menu items // so we can get a fancy scroll animation menuItems.click(function(e){ var href = $(this).attr("href"), offsetTop = href === "#" ? 0 : $(href).offset().top-topMenuHeight+1; $('html, body').stop().animate({ scrollTop: offsetTop // scrollTop: $($(this).attr('href')).offset().top - 150 }, 850); e.preventDefault(); }); // Bind to scroll $(window).scroll(function(){ // Get container scroll position var fromTop = $(this).scrollTop()+topMenuHeight; // Get id of current scroll item var cur = scrollItems.map(function(){ if ($(this).offset().top < fromTop) return this; }); // Get the id of the current element cur = cur[cur.length-1]; var id = cur && cur.length ? cur[0].id : ""; if (lastId !== id) { lastId = id; // Set/remove active class menuItems .parent().removeClass("active") .end().filter("[href=#"+id+"]").parent().addClass("active"); } }); </script> <script src="assets/js/isotope.js"></script> <script src="assets/js/jquery.counterup.min.js"></script> <script src="assets/js/jquery.magnific-popup.min.js"></script> <script src="assets/js/jquery.validate.min.js"></script> <script src="assets/js/owl.carousel.min.js"></script> <script src="assets/js/TweenMax.min.js"></script> <script src="assets/js/jquery.enllax.min.js"></script> <script src="assets/js/waypoints.min.js"></script> <script src="assets/js/wow.min.js"></script> <script src="assets/js/jquery.mCustomScrollbar.concat.min.js"></script> <script src="assets/js/circle-progress.min.js"></script> <script src="assets/js/countdown.min.js"></script> <script src="assets/js/jquery.ajaxchimp.min.js"></script> <script src="assets/js/nouislider.js"></script> <script src="assets/js/jquery.bootstrap-touchspin.min.js"></script> <script src="assets/js/theme.js"></script> <script> $(document).ready(function(){ $('.myslider').owlCarousel({ items:1, nav: true, dots: true, dotsData: true, }); }); </script> </body> </html>

Pages: 1 2 3 4 5 6 7 8 9 10